Introduction: Inflammation is associated with tumor initiation, and existing tumors are associated with immune suppression locally and systemically. Cancer trea…
As reported in The New England Journal of Medicine by Andre et al, interim analysis of the phase III CheckMate 8HW trial has shown that…
The Reagan-Udall Foundation for the FDA is an independent 501(c)(3) not-for-profit organization created by Congress for the purpose of advancing regulatory science – science that…
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology.
This model-based study using population-level cancer mortality data evaluates the association of prevention, screening, and treatment interventions with cumulative number of cancer deaths averted from…
The prevalence of prostate cancer reaches between 30% and 50% in autopsy studies among men who died from other causes.1 With this large occult disease…
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year…
PURPOSEThe advent of new therapeutic modalities highlighted deficiencies in the traditional maximum tolerated dose approach for oncology drug dose selection and prompted the Food and…
It’s mostly the providers overcharging you, not the middlemen.
* Drugs@FDA includes information about drugs, including biological products, approved for human use in the United States (see FAQ), but does not include information about…
PURPOSEWeight gain is a known adverse event (AE) of alectinib. This study evaluates the progression of actual weight gain over time and explores its association…
